ALKS Alkermes plc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1520262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.3%
TTM net income YoY-100.1%
TTM EPS YoY-100.5%
Revenue 3-yr CAGR3.3%
Net income 3-yr CAGR—
Margins
Gross margin82.9%
Operating margin3.7%
Net margin-0.0%
FCF margin13.0%
EBITDA margin8.3%
Returns
ROE-0.0%
ROA-0.0%
ROIC (approx.)1.7%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.80x
Current ratio2.42x
Interest coverage0.74x
Cash quality & payout
Operating cash flow / net income-692.27x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B |
| Cost of revenue | $196.46M | $245.33M | $253.04M | $218.07M | $197.32M |
| Gross profit | $1.28B | $1.31B | $1.41B | $893.73M | $976.43M |
| R&D expense | $323.96M | $245.33M | $270.81M | $272.70M | $290.92M |
| SG&A expense | $701.52M | $645.24M | $689.75M | $590.75M | $549.61M |
| Operating income | $253.96M | $420.64M | $414.12M | -$6.09M | $97.75M |
| Interest expense | $12.28M | $22.58M | $23.03M | $13.04M | $11.22M |
| Pretax income | $291.45M | $443.75M | $421.52M | -$31.13M | $87.73M |
| Income tax | $49.79M | $71.61M | -$97.64M | $2.02M | $11.33M |
| Net income | $241.66M | $367.07M | $355.76M | -$158.27M | -$48.17M |
| EBITDA | $281.12M | $449.17M | $489.05M | $71.77M | $176.40M |
| EPS (basic) | 1.47 | 2.22 | 2.14 | -0.97 | -0.30 |
| EPS (diluted) | 1.43 | 2.17 | 2.10 | -0.97 | -0.29 |
| Weighted avg. shares (diluted) | 168.74M | 169.20M | 169.73M | 163.74M | 164.75M |
| Balance sheet | |||||
| Cash & equivalents | $388.57M | $291.15M | $457.47M | $292.47M | $337.54M |
| Short-term investments | $199.65M | $460.52M | $316.02M | $315.99M | $198.77M |
| Receivables | $334.02M | $384.53M | $332.48M | $287.97M | $313.19M |
| Inventory | $196.62M | $182.89M | $186.41M | $181.42M | $150.34M |
| Current assets | $1.93B | $1.42B | $1.49B | $1.13B | $1.06B |
| PP&E, net | $221.72M | $227.56M | $226.94M | $222.92M | $341.05M |
| Goodwill | $83.03M | $83.03M | $83.03M | $83.03M | $92.87M |
| Intangibles | $815,000 | $890,000 | $1.99M | $37.68M | $74.04M |
| Total assets | $2.49B | $2.06B | $2.14B | $1.96B | $2.02B |
| Current liabilities | $543.44M | $465.20M | $520.22M | $497.74M | $471.29M |
| Short-term debt | $0 | — | $3.00M | $3.00M | $3.00M |
| Long-term debt | $0 | — | $287.73M | $290.27M | $292.80M |
| Total debt | $0 | — | $290.73M | $293.27M | $295.80M |
| Total liabilities | $667.70M | $590.59M | $933.54M | $920.23M | $911.90M |
| Shareholders' equity | $1.82B | $1.46B | $1.20B | $1.04B | $1.11B |
| Net debt | -$388.57M | — | -$166.74M | $797,000 | -$41.74M |
| Shares outstanding | 165.61M | 162.18M | 166.98M | 164.38M | 161.94M |
| Cash flow statement | |||||
| Operating cash flow | $520.75M | $439.12M | $401.35M | $21.04M | $101.72M |
| Capital expenditure | $40.42M | $33.48M | $48.05M | $38.26M | $28.02M |
| Free cash flow | $480.33M | $405.64M | $353.31M | -$17.21M | $73.69M |
| Investing cash flow | $295.50M | -$111.31M | $53.36M | -$64.54M | -$66.20M |
| Financing cash flow | $12.38M | -$494.14M | -$289.71M | -$1.57M | $29.07M |
| Depreciation & amortization | $27.16M | $28.53M | $74.93M | $77.86M | $78.65M |
| Stock-based compensation | $98.72M | $96.64M | $100.91M | $94.25M | $87.62M |
| Share buybacks | — | $200.28M | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.